Coya Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Coya Therapeutics, Inc. (COYA) reported Increase (Decrease) in Accrued Liabilities of -$1.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$162.25K, a 115.77% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.38M, a 427.91% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $849.21K.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$1.20M, a 395.58% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $1.10M.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$1.50M, a 270.66% decline from fiscal 2023.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $877.91K, a 6.21% increase from fiscal 2022.
- Coya Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $826.56K, a 184.22% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$162.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.54M 10-Q · filed 2026-08-11 | -$695.25K derived: sum of 3 quarters · filed 2026-08-11 | -$1.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.38M 10-Q · filed 2026-05-12 | -$532.99K derived: sum of 2 quarters · filed 2026-05-12 | -$1.73M derived: sum of 3 quarters · filed 2026-05-12 | -$703.87K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $849.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$350.77K derived: sum of 2 quarters · filed 2026-03-16 | $678.33K derived: sum of 3 quarters · filed 2026-08-11 | $1.10M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$170.88K derived: sum of 2 quarters · filed 2026-08-11 | $250.65K 10-Q · filed 2025-11-12 | $229.47K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.45M 10-Q · filed 2026-08-11 | $1.43M derived: sum of 3 quarters · filed 2026-08-11 | $1.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $421.52K 10-Q · filed 2026-05-12 | $400.35K derived: sum of 2 quarters · filed 2026-05-12 | $806.33K derived: sum of 3 quarters · filed 2026-05-12 | -$231.95K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$21.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $384.81K derived: sum of 2 quarters · filed 2026-03-16 | -$653.47K derived: sum of 3 quarters · filed 2026-03-16 | -$1.50M 10-K · filed 2026-03-16 |
| 2024-09-30 | $405.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$632.30K derived: sum of 2 quarters · filed 2025-11-12 | -$1.48M 10-Q · filed 2025-11-12 | $236.56K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.88M 10-Q · filed 2025-08-12 | -$169.42K derived: sum of 3 quarters · filed 2025-08-12 | $19.62K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$844.75K 10-Q · filed 2025-05-13 | $868.86K derived: sum of 2 quarters · filed 2025-05-13 | $1.06M derived: sum of 3 quarters · filed 2025-05-13 | $1.32M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.90M derived: sum of 2 quarters · filed 2025-03-18 | $2.16M derived: sum of 3 quarters · filed 2025-03-18 | $877.91K 10-K · filed 2025-03-18 |
| 2023-09-30 | $189.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $447.99K derived: sum of 2 quarters · filed 2024-11-06 | -$835.69K 10-Q · filed 2024-11-06 | -$732.94K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $258.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.02M 10-Q · filed 2024-08-12 | -$921.98K derived: sum of 3 quarters · filed 2024-08-12 | -$232.72K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$1.28M 10-Q · filed 2024-05-09 | -$1.18M derived: sum of 2 quarters · filed 2024-05-09 | -$491.67K derived: sum of 3 quarters · filed 2024-05-09 | -$325.51K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $102.75K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $792.01K derived: sum of 2 quarters · filed 2024-03-19 | $958.16K derived: sum of 3 quarters · filed 2024-03-19 | $826.56K 10-K · filed 2024-03-19 |
| 2022-09-30 | $689.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $855.41K derived: sum of 2 quarters · filed 2023-11-08 | $723.80K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $166.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $34.55K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$131.60K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $290.82K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |